Hybio Pharmaceutical unveils dividend plan, proposes A-share placement for growth

Hybio Pharmaceutical has formulated a three-year dividend return plan for 2025-2027, emphasizing a stable distribution policy. The company commits to an annual cash dividend of no less than 10% of distributable profits, with total cash dividends over any three consecutive years not falling below 30% of the average annual distributable profit. This plan aims to ensure continuous and stable returns for investors.

Concurrently, Hybio Pharmaceutical announced a proposed private placement of A-shares in 2025 to raise up to RMB 968m. The funds are earmarked for several key projects, including expanding its peptide drug production lines (RMB 495m), increasing peptide fragment output (RMB 40m), upgrading R&D laboratories (RMB 55m), and advancing semaglutide research (RMB 98m), with a significant portion (RMB 280m) allocated to supplement working capital. The proposed issuance will not dilute controlling shareholder ownership.

Additionally, the company plans to increase its 2025 annual comprehensive credit and guarantee facilities from RMB 350m to RMB 650m. This adjustment supports the company’s operational needs and ongoing strategic investments, aligning with the financing and dividend strategies to enhance long-term growth and investor value.